View Older Stories View More Recent Stories

Mar 27, 2019 06:06AM Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019
Mar 26, 2019 08:32AM Gilead (GILD) Announces Japan's MHLW Approved its Biktarvy for Treatment of HIV-1 Infection
Mar 26, 2019 08:30AM Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Mar 13, 2019 08:34AM Agenus (AGEN) Secures $7.5M Milestone Payment from Gilead Sciences, Inc. (GILD)
Mar 7, 2019 05:31PM Gilead Sciences (GILD) Announces Data From Two Studies Supporting Further Development of GS-6207
Mar 7, 2019 05:30PM Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
Mar 6, 2019 05:31PM Gilead (GILD) Presents Data on Biktarvy in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance
Mar 6, 2019 05:30PM Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women
Mar 6, 2019 05:30PM Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance
Mar 6, 2019 02:13PM Gilead Sciences (GILD) DISCOVER HIV Trial Meets Primary and Secondary Endpoints
Mar 6, 2019 02:10PM Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection
Mar 5, 2019 04:31PM Gilead Sciences (GILD) EVP of Oncology Therapeutics, Alessandro Riva, to Leave
Mar 5, 2019 04:30PM Gilead Announces Senior Management Change
Mar 5, 2019 04:05PM Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12
Feb 11, 2019 04:32PM Gilead Sciences (GILD) Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to NASH Doesn't Meet Primary Endpoint
Feb 11, 2019 04:30PM Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Feb 4, 2019 04:02PM Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend
Jan 24, 2019 08:30AM Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead
Jan 22, 2019 04:05PM Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019
Jan 8, 2019 01:00AM Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)
Jan 6, 2019 05:30PM Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
Jan 2, 2019 09:01AM Gilead Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7
Dec 20, 2018 08:28AM Agenus (AGEN), Gilead Sciences, Inc. (GILD) Announces Collaboration to Develop Immuno-Oncology Therapies
Dec 20, 2018 07:30AM Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies
Dec 20, 2018 07:30AM Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies
Dec 19, 2018 08:02AM Gilead Sciences (GILD), Scholar Rock (SRRK) Announce Pact to Develop Novel Therapies for Fibrotic Diseases
Dec 19, 2018 08:01AM Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases
Dec 10, 2018 05:51AM Gilead Sciences (GILD) Announces Daniel O’Day as Board Chairman & CEO
Dec 10, 2018 01:00AM Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer
Dec 4, 2018 08:33AM Gilead Sciences (GILD) Announces China's NMPA Approves Harvoni for Treatment of Chronic HCV Genotype 1-6
Dec 4, 2018 08:30AM China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Dec 4, 2018 08:30AM China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6
Dec 3, 2018 08:00PM Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Dec 2, 2018 12:04PM Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma
Nov 18, 2018 10:00PM China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection
Nov 12, 2018 05:01PM Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27
Nov 9, 2018 08:01AM Gilead Sciences (GILD) Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting
Nov 9, 2018 08:00AM Gilead Sciences (GILD) Announces Positive Phase 2 Results for GS-9674 in Primary PSC at The Liver Meeting
Nov 9, 2018 08:00AM Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018
Nov 9, 2018 08:00AM Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018
Nov 9, 2018 08:00AM Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
Nov 1, 2018 09:00AM Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018
Oct 30, 2018 07:17AM Gilead Sciences (GILD) Reports 96-Wk Data from Phase 3 Study of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for HIV-1 Treatment in Adults New to HIV Therapy
Oct 30, 2018 06:36AM Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
Oct 25, 2018 04:02PM Gilead Sciences Announces Fourth Quarter 2018 Dividend
Oct 11, 2018 04:05PM Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018
Oct 11, 2018 03:24PM Gilead Sciences (GILD) to Present New Data on Treatment and Diagnosis of Liver Diseases at Liver Meeting
Oct 11, 2018 03:23PM Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018
Oct 3, 2018 08:32AM Gilead Sciences (GILD) Reports 96-Week Results From Phase 3 Study of Biktarvy for Treatment of HIV-1 in Adults New to HIV Therapy
Oct 3, 2018 08:30AM Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
View More Recent Stories View Older Stories